Results 1 to 10 of about 30,536 (239)

DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t(8;21) acute myeloid leukemia

Clinical Epigenetics, 2023
Background Despite its inconsistent response rate, decitabine, a demethylating agent, is often used as a non-intensive alternative therapeutic agent for acute myeloid leukemia (AML). It has been reported that relapsed/refractory AML patients with t(8;21)
Shujiao He, Yan Li, Xuanren Shi, Lei Wang, Diya Cai, Jingfeng Zhou, Li Yu   +6 more
doaj   +2 more sources

Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report

Cardio-Oncology, 2023
Background Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for the treatment of chronic myelomonocytic leukemia (CMML).
Ankur Sheel, Junu Bae, Ashlee Asada, Gregory A. Otterson, Ragavendra R. Baliga, Kristin L. Koenig   +5 more
doaj   +2 more sources

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma

Cancer Medicine, 2023
Background There is an urgent need for effective treatment of patients with relapsed/refractory diffuse large B‐cell lymphoma (R/R‐DLBCL). This trial investigated the efficacy of decitabine in combination with rituximab, cisplatin, cytarabine ...
Xiaoshuang Kong, Xudong Zhang, Mengjie Ding, Xiaoyan Feng, Meng Dong, Lei Zhang, Xiaorui Fu, Ling Li, Xin Li, Zhenchang Sun, Jiaqin Yan, Xinhua Wang, Xiaolong Wu, Qingjiang Chen, Mingzhi Zhang, Linan Zhu   +15 more
doaj   +2 more sources

Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas

Clinical Epigenetics, 2023
Background Targeting the epigenome of cancerous diseases represents an innovative approach, and the DNA methylation inhibitor decitabine is recommended for the treatment of hematological malignancies.
Zijiao Tang, Lu Liu, Jürgen Borlak
doaj   +2 more sources

Decitabine in the treatment of acute myeloid leukemia in elderly patients [PDF]

Cancer Management and Research, 2014
Priya Malik, Amanda F CashenWashington University School of Medicine, St Louis, MO, USAAbstract: The majority of patients with acute myeloid leukemia (AML) are elderly and have a poor prognosis despite induction therapy. Decitabine, a DNA-hypomethylating
Malik P, Cashen AF
doaj   +4 more sources

Economic Burden of Intravenous Decitabine Administration in Patients Affected by Acute Myeloid Leukemia Ineligible for Induction Chemotherapy and Impact of Oral Formulation Introduction: A Micro-Costing Study in Italy [PDF]

ClinicoEconomics and Outcomes Research
Alessandra Di Costanzo, Luca Loreto, Chiara Vassallo, Francesca Fiorentino Real World Solutions, IQVIA Solutions Italy S.r.l., Milan, ItalyCorrespondence: Chiara Vassallo, Real World Solutions, IQVIA Solutions Italy s.r.l., Via Fabio Filzi 29, Milan ...
Di Costanzo A, Loreto L, Vassallo C, Fiorentino F   +3 more
doaj   +2 more sources

Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ+ CD4+ T Cells Through Enhancing IκBα Degradation and NF-κB Activation

Frontiers in Cell and Developmental Biology, 2021
BackgroundCD4+ T cells play multiple roles in controlling tumor growth and increasing IFN-γ+ T-helper 1 cell population could promote cell-mediated anti-tumor immune response.
Xiang Li, Xiang Li, Liang Dong, Jiejie Liu, Chunmeng Wang, Yan Zhang, Qian Mei, Weidong Han, Ping Xie, Jing Nie   +9 more
doaj   +1 more source

Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction. [PDF]

PLoS ONE, 2014
Efficient ex vivo transduction of hematopoietic stem cells (HSCs) is encumbered by differentiation which reduces engraftment. We hypothesized that inhibiting DNA methyltransferase with decitabine would block differentiation of transduced CD34+ cells ...
Naoya Uchida, Matthew M Hsieh, Charlotte Platner, Yogen Saunthararajah, John F Tisdale   +4 more
doaj   +1 more source

Absence of early platelet increment in healthy mice during decitabine treatment

Scientific Reports, 2022
Treatment of myelodysplastic syndromes includes the administration of the hypomethylating agent decitabine. An early platelet response in decitabine-treated myelodysplastic syndrome patients is a predictor of overall survival. The effect of decitabine on
Juliane Baumann, Markus Spindler, Yannick Throm, Michael Lübbert, Markus Bender   +4 more
doaj   +1 more source

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes

Cells, 2021
Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disease characterized by inefficient hematopoiesis and the potential development of acute leukemia.
Seungyoun Kim, Dong-Yeop Shin, Dayeon Kim, Somi Oh, Junshik Hong, Inho Kim, Eunju Kim   +6 more
doaj   +1 more source